Search Results - "YEL, M"

Arthroscopic treatment of osteochondral lesion of olecranon by Bilge, O., Yel, M., Buyukbebeci, O., Doral, M. N.

“…Issue Title: Cartilage, the troublesome tissue. Updates on Cartilage repair 2014…”
Get full text

Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats by Kalender, S, Kalender, Y, Ates, A, Yel, M, Olcay, E, Candan, S

“…Idarubicin is an anthracycline antibiotic extensively used in acute leukemia. In the present study we investigated whether vitamin E and catechin can reduce…”
Get full text

Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin by KALENDER, Yusuf, YEL, Mustafa, KALENDER, Suna

“…Doxorubicin (DXR) is an anthracycline antibiotic, broadly used in tumor therapy. In the present study we investigated whether vitamin E and catechin can reduce…”
Get full text

Results of decompression and rotator cuff repair in patients 65 years old and older: 6- to 14-year follow-up by Yel, M, Shankwiler, J A, Noonan, Jr, J E, Burkhead, Jr, W Z

“…At an average of 9.2 years after surgery, 47 patients with 51 shoulders who had undergone rotator cuff repair and subacromial decompression through an open…”
Get more information

The pelvic external fixation : the mid-term results of 41 patients treated with a newly designed fixator by ARAZI, Mehmet, KUTLU, Abdurrahman, MUTLU, Mahmut, YEL, Mustafa, KAPICIGLU, M. I

“…The purpose of this study was to evaluate the clinical and radiological results of unstable pelvic fractures treated with a new external fixation device…”
Get full text

Halothane hepatotoxicity and hepatic free radical metabolism in guinea pigs ; the effects of vitamin E by DURAK, I, GÜVEN, T, BIREY, M, ÖZTÜRK, H. S, KURTIPEK, Ö, YEL, M, DIKMEN, B, CANBOLAT, O, KAVUTCU, M, KACMAZ, M

“…The aim of this study was to investigate the relation between halothane hepatotoxicity and hepatic free radical metabolism and to establish a possible…”
Get full text

Impaired antioxidant defence in guinea pig heart tissues treated with halothane by DURAK, I, KURTIPEK, O, ÖZTÜRK, H. S, BIREY, M, GÜVEN, T, KAVUTCU, M, KACMAZ, M, DIKMEN, B, YEL, M, CANBOLAT, O

“…To investigate the effects of halothane and halothane plus vitamin E treatment on myocardial free radical metabolism in guinea pigs. Four groups of seven…”
Get full text

Ilizarov external fixation for severely comminuted supracondylar and intercondylar fractures of the distal femur by Arazi, M., Memik, R., Ögün, T. C., Yel, M.

Get full text

Ilizarov external fixation for severely comminuted supracondylar and intercondylar fractures of the distal femur by ARAZI, M, MEMIK, R, ÖGÜN, T. C, YEL, M

“…Our aim was to determine the clinical effectiveness and safety of Ilizarov external fixation for the acute treatment of severely comminuted extra-articular and…”
Get full text

Osteoid osteoma of the carpal bones by ARAZI, Mehmet, MEMIK, Recep, YEL, Mustafa, ÖGÜN, Tunc C

“…Osteoid osteoma is a benign bone tumor that rarely localizes in the hand or the carpal bones. We report two cases of osteoid osteoma localized in two different…”
Get full text

Improved Treatment Satisfaction with a New Human Subcutaneous Immunoglobulin (SCIG 20%) in Patients Previously Treated with IVIG by Meckley, Lisa, PhD, Ito, Diane, MA, Hu, Xingdi, PhD, Berner, Todd, MD, Yel, Leman, MD, FAAAAI

“…Patients also reported improvement relative to the IVIG therapy period after treatment with SCIG 20% in the Therapy Setting LQI domain, improving from 17.5 to…”
Get full text

Analysis of Safety and Tolerability Data in Pediatric Patients with Primary Immunodeficiency Diseases from Two Phase 2/3 Studies of Human Immune Globulin Subcutaneous, 20 by Paris, Kenneth, MD, MPH, Haddad, Elie, MD, PhD, Hussain, Iftikhar, Brodszki, Nicholas, MD, PhD, Darter, Amy Liebl, MD, FAAAAI, Engl, Werner, PhD, McCoy, Barbara, PhD, Yel, Leman, MD, FAAAAI

“…Conclusions SCIG 20% treatment was safe and well tolerated at high infusion rates and volumes per site with short infusion durations, offering a favorable Ig…”
Get full text

A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America by Suez, Daniel, MD, FAAAAI, Krivan, Gregely, PhD, Jolles, Stephen R., MD, Hussain, Iftikhar, Stein, Mark R., MD, FAAAAI, Gupta, Sudhir, MD, Ph.D, MACP, Paris, Kenneth, MD, MPH, van Hagen, Martin, Brodszki, Nicholas, MD, PhD, McCoy, Barbara, PhD, Yel, Leman, MD FAAAAI

“…Rationale Cuvitru, a new human immune globulin (Ig) subcutaneous, 20% (SCIG 20%) ready-for-use, liquid preparation of highly purified human IgG, was well…”
Get full text

Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs) by Gupta, Sudhir, MD, PhD, MACP, Stein, Mark R., MD, FAAAAI, Melamed, Isaac Reuven, MD, Hussain, Iftikhar, Paris, Kenneth, MD, MPH, Engl, Werner, PhD, McCoy, Barbara, PhD, Rabbat, Christopher J., PhD, Yel, Leman, MD, FAAAAI

“…Rationale Data from a phase 2/3 North American clinical trial provided an opportunity to understand the onboarding experience of a new SCIG 20% in patients…”
Get full text

Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies by Wasserman, Richard L., MD, PhD, FAAAAI, Gupta, Sudhir, MD, PhD, MACP, Stein, Mark R., MD, FAAAAI, Melamed, Isaac Reuven, MD, Puck, Jennifer M., MD, Engl, Werner, PhD, Leibl, Heinz, PhD, Rabbat, Christopher J., PhD, Yel, Leman, MD, FAAAAI

“…Conclusions Long-term evaluation of the same patient cohort over three consecutive studies demonstrated that IGHy, compared to the other modes of Ig therapy…”
Get full text

Old Unreduced Posterior Sternoclavicular Dislocation and Coracoid Impingement by Yel, Mustafa, Parham, Michael, Burkhead, W. Z.

Get full text

Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America by Suez, Daniel, MD, FAAAAI, Melamed, Isaac, MD, Hussain, Iftikhar, MD, FAAAAI, Stein, Mark R., MD, FAAAAI, Gupta, Sudhir, MD, PhD, FAAAAI, Paris, Kenneth, MD, MPH, Fritsch, Sandor, PhD, Bourgeois, Christelle, PhD, Leibl, Heinz, PhD, McCoy, Barbara, PhD, Yel, Leman, MD, FAAAAI

“…Results Seventy-four patients aged 3-83 years received IGSC 20% and 67 completed; no patient discontinued IGSC 20% due to a serious adverse event (SAE) or…”
Get full text

Bedside sonographic measurement of optic nerve sheath diameter as a predictor of intracranial pressure in Emergency Department by Komut, Erdal, MD, Kozacı, Nalan, Sönmez, Bedriye Müge, MD, Yılmaz, Fevzi, MD, Komut, Seval, MD, Yıldırım, Zeliha Nilgün, MD, Beydilli, İnan, MD, Yel, Cihat, MD

“…Abstract Background Ocular ultrasonography (USG) of optic nerve sheath diameter (ONSD) to determine intracranial pressure (ICP) has become favorable in recent…”
Get full text

Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies by Stein, Mark R., MD, FAAAAI, Wasserman, Richard L., MD, PhD, FAAAAI, Melamed, Isaac, MD, Gupta, Sudhir, MD, PhD, FAAAAI, Kobrynski, Lisa J., MD, MPH, FAAAAI, Rubinstein, Arye, MD, FAAAAI, Rabbat, Christopher J., PhD, Engl, Werner, PhD, McCoy, Barbara, PhD, Leibl, Heinz, PhD, Yel, Leman, MD, FAAAAI

“…Rationale IGHy can be administered at similar doses/volumes and dosing intervals as intravenous immunglobulin G (IgG) (IGIV) but, similar to conventional…”
Get full text

Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (IGHy) in Patients with Primary Immunodeficiency Disease (PIDD): Infections over Time by Wasserman, Richard L., MD, PhD, FAAAAI, Stein, Mark R., MD, FAAAAI, Kobrynski, Lisa J., MD, MPH, FAAAAI, Gupta, Sudhir, MD, PhD, FAAAAI, Grant, J. Andrew, MD, FAAAAI, Rubinstein, Arye, MD, FAAAAI, Rabbat, Christopher J., PhD, Engl, Werner, PhD, McCoy, Barbara, PhD, Leibl, Heinz, PhD, Yel, Leman, MD, FAAAAI

“…Over the course of IGHy treatment, serum trough levels of antibodies to Haemophilus influenza, Clostridium tetani toxoid, and hepatitis B virus were protective…”
Get full text